Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas

Clinically HER2+ (cHER2+) breast cancer (BC) can no longer be considered a single BC disease entity in terms of trastuzumab responsiveness. Here we propose a framework for predicting the response of cHER2+ to trastuzumab that integrates the molecular distinctions of intrinsic BC subtypes with recent...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncotarget
Autori principali: Martin-Castillo, Begoña, Lopez-Bonet, Eugeni, Cuyàs, Elisabet, Viñas, Gemma, Pernas, Sonia, Dorca, Joan, Menendez, Javier A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Impact Journals LLC 2015
Soggetti:
Research Perspective
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4741696/
https://ncbi.nlm.nih.gov/pubmed/26474458
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi